# fep-benchmark
Benchmark set for relative free energy calculations.

Created by Christina Schindler and Daniel Kuhn, Merck KGaA, Darmstadt, Germany.

December 2018

## References for datasets used in benchmark

### c-Met
Dorsch, Dieter, et al. 
"Identification and optimization of pyridazinones
 as potent and selective c-Met kinase inhibitors." 
Bioorganic & medicinal chemistry letters 25.7 (2015): 1597-1602.


### Eg5
Schiemann, Kai, et al. 
"The discovery and optimization of hexahydro-2H-pyrano
 [3, 2-c] quinolines (HHPQs) as potent and selective inhibitors
 of the mitotic kinesin-5." 
 Bioorganic & medicinal chemistry letters 20.5 (2010): 1491-1495.
 
 ### Hif2a
Wallace, Eli M., et al. 
"A small-molecule antagonist of HIF2α is efficacious
in preclinical models of renal cell carcinoma." 
Cancer research 76.18 (2016): 5491-5500.

Dixon, Darryl David, et al. 
"Aryl ethers and uses thereof." U.S. Patent No. 9,908,845. 6 Mar. 2018.

### PFKFB3
Boutard, Nicolas, et al. 
"Discovery and Structure–Activity Relationships of N-Aryl 
6-Aminoquinoxalines as Potent PFKFB3 Kinase Inhibitors."
ChemMedChem 14.1 (2019): 169-181.
 
 
### SHP2
Chen, Ying-Nan P., et al. 
"Allosteric inhibition of SHP2 phosphatase inhibits cancers
 driven by receptor tyrosine kinases." Nature 535.7610 (2016): 148.
 
Garcia Fortanet, Jorge, et al. 
"Allosteric inhibition of SHP2: identification of a potent, selective,
and orally efficacious phosphatase inhibitor."
Journal of medicinal chemistry 59.17 (2016): 7773-7782.

Chen, Christine Hiu-tung, et al. 
"1-pyridazin-/triazin-3-yl-piper (-azine)/idine/pyrolidine derivatives
and compositions thereof for inhibiting the activity of shp2." 
U.S. Patent Application No. 15/110,498.
